Cargando…

Posterior Reversible Encephalopathy Syndrome Onset Within 24 Hours Following Moderna mRNA Booster COVID-19 Vaccination: Vaccine Adverse Event Vs. Hypertension?

We present a case of a female who presented with the acute onset of neurological changes within 24 hours of receiving her third, or booster, dose of the mRNA Moderna (Cambridge, Massachusetts) coronavirus disease 2019 (COVID-19) vaccination. Her clinicoradiological findings were most consistent with...

Descripción completa

Detalles Bibliográficos
Autores principales: McCullough, Jocelyn, Ahmad, Manal, Tam, Idy, Portnoy, Reid, Ng, Joseph, Zachary, Kuschner, Kaell, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187357/
https://www.ncbi.nlm.nih.gov/pubmed/35706738
http://dx.doi.org/10.7759/cureus.24919
_version_ 1784725149655760896
author McCullough, Jocelyn
Ahmad, Manal
Tam, Idy
Portnoy, Reid
Ng, Joseph
Zachary, Kuschner
Kaell, Alan
author_facet McCullough, Jocelyn
Ahmad, Manal
Tam, Idy
Portnoy, Reid
Ng, Joseph
Zachary, Kuschner
Kaell, Alan
author_sort McCullough, Jocelyn
collection PubMed
description We present a case of a female who presented with the acute onset of neurological changes within 24 hours of receiving her third, or booster, dose of the mRNA Moderna (Cambridge, Massachusetts) coronavirus disease 2019 (COVID-19) vaccination. Her clinicoradiological findings were most consistent with posterior reversible encephalopathy syndrome (PRES). Although PRES has been reported with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, this raised suspicion of a possible vaccine-induced PRES with her only confounder being hypertension managed with a beta-blocker. Extensive workup for other entities associated with PRES, including infection, autoimmune, paraneoplastic syndrome, and alcohol were unrevealing. Thus far, there have not been any reports of PRES post mRNA vaccination. We encourage providers to report similar cases with neurological manifestations post mRNA vaccination to the vaccine adverse event reporting system (VAERS). Timely diagnosis and treatment of PRES may help minimize any irreversible neurological sequelae.
format Online
Article
Text
id pubmed-9187357
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-91873572022-06-14 Posterior Reversible Encephalopathy Syndrome Onset Within 24 Hours Following Moderna mRNA Booster COVID-19 Vaccination: Vaccine Adverse Event Vs. Hypertension? McCullough, Jocelyn Ahmad, Manal Tam, Idy Portnoy, Reid Ng, Joseph Zachary, Kuschner Kaell, Alan Cureus Cardiology We present a case of a female who presented with the acute onset of neurological changes within 24 hours of receiving her third, or booster, dose of the mRNA Moderna (Cambridge, Massachusetts) coronavirus disease 2019 (COVID-19) vaccination. Her clinicoradiological findings were most consistent with posterior reversible encephalopathy syndrome (PRES). Although PRES has been reported with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, this raised suspicion of a possible vaccine-induced PRES with her only confounder being hypertension managed with a beta-blocker. Extensive workup for other entities associated with PRES, including infection, autoimmune, paraneoplastic syndrome, and alcohol were unrevealing. Thus far, there have not been any reports of PRES post mRNA vaccination. We encourage providers to report similar cases with neurological manifestations post mRNA vaccination to the vaccine adverse event reporting system (VAERS). Timely diagnosis and treatment of PRES may help minimize any irreversible neurological sequelae. Cureus 2022-05-11 /pmc/articles/PMC9187357/ /pubmed/35706738 http://dx.doi.org/10.7759/cureus.24919 Text en Copyright © 2022, McCullough et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
McCullough, Jocelyn
Ahmad, Manal
Tam, Idy
Portnoy, Reid
Ng, Joseph
Zachary, Kuschner
Kaell, Alan
Posterior Reversible Encephalopathy Syndrome Onset Within 24 Hours Following Moderna mRNA Booster COVID-19 Vaccination: Vaccine Adverse Event Vs. Hypertension?
title Posterior Reversible Encephalopathy Syndrome Onset Within 24 Hours Following Moderna mRNA Booster COVID-19 Vaccination: Vaccine Adverse Event Vs. Hypertension?
title_full Posterior Reversible Encephalopathy Syndrome Onset Within 24 Hours Following Moderna mRNA Booster COVID-19 Vaccination: Vaccine Adverse Event Vs. Hypertension?
title_fullStr Posterior Reversible Encephalopathy Syndrome Onset Within 24 Hours Following Moderna mRNA Booster COVID-19 Vaccination: Vaccine Adverse Event Vs. Hypertension?
title_full_unstemmed Posterior Reversible Encephalopathy Syndrome Onset Within 24 Hours Following Moderna mRNA Booster COVID-19 Vaccination: Vaccine Adverse Event Vs. Hypertension?
title_short Posterior Reversible Encephalopathy Syndrome Onset Within 24 Hours Following Moderna mRNA Booster COVID-19 Vaccination: Vaccine Adverse Event Vs. Hypertension?
title_sort posterior reversible encephalopathy syndrome onset within 24 hours following moderna mrna booster covid-19 vaccination: vaccine adverse event vs. hypertension?
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187357/
https://www.ncbi.nlm.nih.gov/pubmed/35706738
http://dx.doi.org/10.7759/cureus.24919
work_keys_str_mv AT mcculloughjocelyn posteriorreversibleencephalopathysyndromeonsetwithin24hoursfollowingmodernamrnaboostercovid19vaccinationvaccineadverseeventvshypertension
AT ahmadmanal posteriorreversibleencephalopathysyndromeonsetwithin24hoursfollowingmodernamrnaboostercovid19vaccinationvaccineadverseeventvshypertension
AT tamidy posteriorreversibleencephalopathysyndromeonsetwithin24hoursfollowingmodernamrnaboostercovid19vaccinationvaccineadverseeventvshypertension
AT portnoyreid posteriorreversibleencephalopathysyndromeonsetwithin24hoursfollowingmodernamrnaboostercovid19vaccinationvaccineadverseeventvshypertension
AT ngjoseph posteriorreversibleencephalopathysyndromeonsetwithin24hoursfollowingmodernamrnaboostercovid19vaccinationvaccineadverseeventvshypertension
AT zacharykuschner posteriorreversibleencephalopathysyndromeonsetwithin24hoursfollowingmodernamrnaboostercovid19vaccinationvaccineadverseeventvshypertension
AT kaellalan posteriorreversibleencephalopathysyndromeonsetwithin24hoursfollowingmodernamrnaboostercovid19vaccinationvaccineadverseeventvshypertension